XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue
 9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recognizes revenue in accordance with ASC 606 on the basis of its satisfaction of outstanding performance obligations. The Company typically fulfills its performance obligations over time, either over the course of a single treatment (fee-for-service or "FFS"), a month (capitation), or a number of months (clinical research). The Company also has revenue that is satisfied at a point in time (dispensary). See Note 2 for summary of the Company’s policies and significant assumptions related to revenue recognition.
Disaggregation of Revenue
The Company categorizes revenue based on various factors such as the nature of contracts, payors, order to billing arrangements, and cash flows received by the Company, as follows:
(in thousands)Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Patient services  
Capitated revenue$18,056 $16,355 $51,410 $44,815 
FFS revenue35,57828,272105,923 73,978 
Subtotal53,634 44,627 157,333 118,793 
Dispensary revenue26,792 18,839 76,228 57,736 
Clinical research trials and other revenue1,609 1,511 4,890 4,530 
Total$82,035 $64,977 $238,451 $181,059 
Refer to Note 20 for Segment Reporting for disaggregation of revenue by reporting segment.
Contract Asset and Liabilities
Under ASC 606, contract assets represent rights to payment for performance contingent on something other than the passage of time and accounts receivable are rights to payment for performance without contingencies. The Company does not have any contract assets as of September 30, 2023 and December 31, 2022. Refer to Note 4 for accounts receivable as of September 30, 2023 and December 31, 2022.
Contract liabilities represent cash that has been received for contracts, but for which performance is still unsatisfied. As of September 30, 2023 and December 31, 2022, contract liabilities amounted to $545 and $1,139, respectively. Contract liabilities are included within other current liabilities and presented in Note 9 along with refund liabilities due to materiality.
Remaining Unsatisfied Performance Obligations
The accounting terms for the Company’s patient services and dispensary contracts do not extend past a year in duration. Additionally, the Company applies the ‘as invoiced’ practical expedient to its clinical research contracts.